This ALK point mutation is discovered in the alectinib-acquired-resistant NSCLC H3122 cell line and it has been proven to be resistant to crizotinib and alectinib but sensitive to ceritinib (17). This evidence concerns the gene ALK and non-small cell lung carcinoma.